Literature DB >> 35098369

Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.

Hideyuki Arita1,2, Koichi Ichimura3.   

Abstract

TERT promoter mutations are one of the most common genetic alterations in adult-type diffuse gliomas and show specific patterns compared with other genetic alterations according to glioma subtypes. This mutation has variable impacts on patient outcomes in association with other genetic alterations, including IDH1/2 mutations or histological types. The purpose of this paper is to review the current knowledge on the values of TERT promoter mutations in the diagnosis and prognostication of adult-type diffuse gliomas. We also aimed to discuss the interaction between the prognostic impacts of TERT promoter mutations and other molecular alterations. Although its impact on prognosis is somewhat complicated and enigmatic, the mutational status of the TERT promoter provides highly useful information for predicting patients' outcomes in the conventional classification of gliomas defined by IDH1/2 and 1p/19q status.
© 2021. The Author(s) under exclusive licence to The Japan Society of Brain Tumor Pathology.

Entities:  

Keywords:  Glioblastoma; Glioma; IDH; TERT

Year:  2022        PMID: 35098369     DOI: 10.1007/s10014-021-00424-z

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  53 in total

1.  Response to letter to the editor by Moudgil-Joshi and Kaliaperumal.

Authors:  David N Louis; Ian A Cree
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

2.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Authors:  Patrick J Killela; Zachary J Reitman; Yuchen Jiao; Chetan Bettegowda; Nishant Agrawal; Luis A Diaz; Allan H Friedman; Henry Friedman; Gary L Gallia; Beppino C Giovanella; Arthur P Grollman; Tong-Chuan He; Yiping He; Ralph H Hruban; George I Jallo; Nils Mandahl; Alan K Meeker; Fredrik Mertens; George J Netto; B Ahmed Rasheed; Gregory J Riggins; Thomas A Rosenquist; Mark Schiffman; Ie-Ming Shih; Dan Theodorescu; Michael S Torbenson; Victor E Velculescu; Tian-Li Wang; Nicolas Wentzensen; Laura D Wood; Ming Zhang; Roger E McLendon; Darell D Bigner; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

3.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

5.  Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.

Authors:  Hideyuki Arita; Yoshitaka Narita; Shintaro Fukushima; Kensuke Tateishi; Yuko Matsushita; Akihiko Yoshida; Yasuji Miyakita; Makoto Ohno; V Peter Collins; Nobutaka Kawahara; Soichiro Shibui; Koichi Ichimura
Journal:  Acta Neuropathol       Date:  2013-06-14       Impact factor: 17.088

6.  TERT Promoter Mutations and Risk of Recurrence in Meningioma.

Authors:  Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling
Journal:  J Natl Cancer Inst       Date:  2015-12-13       Impact factor: 13.506

7.  TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.

Authors:  Marc Remke; Vijay Ramaswamy; John Peacock; David J H Shih; Christian Koelsche; Paul A Northcott; Nadia Hill; Florence M G Cavalli; Marcel Kool; Xin Wang; Stephen C Mack; Mark Barszczyk; A Sorana Morrissy; Xiaochong Wu; Sameer Agnihotri; Betty Luu; David T W Jones; Livia Garzia; Adrian M Dubuc; Nataliya Zhukova; Robert Vanner; Johan M Kros; Pim J French; Erwin G Van Meir; Rajeev Vibhakar; Karel Zitterbart; Jennifer A Chan; László Bognár; Almos Klekner; Boleslaw Lach; Shin Jung; Ali G Saad; Linda M Liau; Steffen Albrecht; Massimo Zollo; Michael K Cooper; Reid C Thompson; Oliver O Delattre; Franck Bourdeaut; François F Doz; Miklós Garami; Peter Hauser; Carlos G Carlotti; Timothy E Van Meter; Luca Massimi; Daniel Fults; Scott L Pomeroy; Toshiro Kumabe; Young Shin Ra; Jeffrey R Leonard; Samer K Elbabaa; Jaume Mora; Joshua B Rubin; Yoon-Jae Cho; Roger E McLendon; Darell D Bigner; Charles G Eberhart; Maryam Fouladi; Robert J Wechsler-Reya; Claudia C Faria; Sidney E Croul; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Peter B Dirks; William A Weiss; Ulrich Schüller; Ian F Pollack; Stefan Rutkowski; David Meyronet; Anne Jouvet; Michelle Fèvre-Montange; Nada Jabado; Marta Perek-Polnik; Wieslawa A Grajkowska; Seung-Ki Kim; James T Rutka; David Malkin; Uri Tabori; Stefan M Pfister; Andrey Korshunov; Andreas von Deimling; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2013-10-31       Impact factor: 17.088

8.  Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.

Authors:  Andrey Korshunov; Dominik Sturm; Marina Ryzhova; Volker Hovestadt; Marco Gessi; David T W Jones; Marc Remke; Paul Northcott; Arie Perry; Daniel Picard; Marc Rosenblum; Manila Antonelli; Eleonora Aronica; Ulrich Schüller; Martin Hasselblatt; Adelheid Woehrer; Olga Zheludkova; Ella Kumirova; Stephanie Puget; Michael D Taylor; Felice Giangaspero; V Peter Collins; Andreas von Deimling; Peter Lichter; Annie Huang; Torsten Pietsch; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2013-12-14       Impact factor: 17.088

9.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Authors:  M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

10.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Authors:  Hideyuki Arita; Kai Yamasaki; Yuko Matsushita; Taishi Nakamura; Asanao Shimokawa; Hirokazu Takami; Shota Tanaka; Akitake Mukasa; Mitsuaki Shirahata; Saki Shimizu; Kaori Suzuki; Kuniaki Saito; Keiichi Kobayashi; Fumi Higuchi; Takeo Uzuka; Ryohei Otani; Kaoru Tamura; Kazutaka Sumita; Makoto Ohno; Yasuji Miyakita; Naoki Kagawa; Naoya Hashimoto; Ryusuke Hatae; Koji Yoshimoto; Naoki Shinojima; Hideo Nakamura; Yonehiro Kanemura; Yoshiko Okita; Manabu Kinoshita; Kenichi Ishibashi; Tomoko Shofuda; Yoshinori Kodama; Kanji Mori; Yusuke Tomogane; Junya Fukai; Koji Fujita; Yuzo Terakawa; Naohiro Tsuyuguchi; Shusuke Moriuchi; Masahiro Nonaka; Hiroyoshi Suzuki; Makoto Shibuya; Taketoshi Maehara; Nobuhito Saito; Motoo Nagane; Nobutaka Kawahara; Keisuke Ueki; Toshiki Yoshimine; Etsuo Miyaoka; Ryo Nishikawa; Takashi Komori; Yoshitaka Narita; Koichi Ichimura
Journal:  Acta Neuropathol Commun       Date:  2016-08-08       Impact factor: 7.578

View more
  1 in total

1.  Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.

Authors:  Nayuta Higa; Toshiaki Akahane; Seiya Yokoyama; Hajime Yonezawa; Hiroyuki Uchida; Shingo Fujio; Mari Kirishima; Kosuke Takigawa; Nobuhiro Hata; Keita Toh; Junkoh Yamamoto; Ryosuke Hanaya; Akihide Tanimoto; Koji Yoshimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-08-27       Impact factor: 2.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.